ASCENT-1: STX-003 Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 2, open-label trial of STX-003 in solid tumor, non-small cell lung cancer (NSCLC) and melanoma (4 arms), sponsored by Strand Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Serious Adverse Events, and Dose-Limiting Toxicities and Changes from baseline in clinical safety laboratory values and vital signs. Started Jun 2026; status: recruiting.